Temozolomide (TMZ) chemotherapy, in combination with maximal safe resection and radiotherapy, is the current standard of care for patients with glioblastoma (GBM). Despite this multimodal approach, GBM inevitably relapses primarily due to resistance to chemo-radiotherapy, and effective treatment is not available for recurrent disease. In this study we identified TMZ resistant patient-derived primary and previously treated recurrent GBM stem cells (GSC), and investigated the therapeutic activity of a pro-apoptotic variant of oHSV (oHSV-TRAIL) in vitro and in vivo. We show that oHSV-TRAIL modulates cell survival and MAP Kinase proliferation signaling pathways as well as DNA damage response pathways in both primary and recurrent TMZ-resistant GSC. Utilizing real time in vivo imaging and correlative immunohistochemistry, we show that oHSV-TRAIL potently inhibits tumor growth and extends survival of mice bearing TMZ-insensitive recurrent intracerebral GSC tumors via robust and selective induction of apoptosis-mediated death in tumor cells, resulting in cures in 40% of the treated mice. In comparison, the anti-tumor effects in a primary chemoresistant GSC GBM model exhibiting a highly invasive phenotype were significant but less prominent. This work thus demonstrates the ability of oHSV-TRAIL to overcome the therapeutic resistance and recurrence of GBM, and provides a basis for its testing in a GBM clinical trial.
Glioblastoma (GBM) is the most common and aggressive primary brain cancer in adults. 1 Temozolomide (TMZ) chemotherapy, in combination with maximal safe resection and radiotherapy, is the current standard of care for patients with GBM. 2 Despite this multimodal approach, GBM inevitably relapses and the median survival of GBM patients remains only about 15 months. 1, 3 The major reasons for tumor relapse include: (i) incomplete surgical resection due to the invasive nature of GBM, and (ii) molecular deregulation of cell death pathways that contribute to intrinsic resistance to cytocidal therapies (recently reviewed in Ref. 4) . The orally available alkylating agent TMZ induces O6-methyl guanine, causing accumulations of DNA mismatch, subsequent growth arrest, and ultimately apoptosis. 5 Unfortunately, however, almost half of GBMs are TMZ resistant primarily due to the expression of O6-methytlguanine-DNA-methyltransferase (MGMT), which antagonizes the TMZ effect. 6 There is no standard therapy for recurrent GBM and rigorous efforts to investigate molecular targeted agents have not achieved significant extension of overall survival in GBM patients. 7 Thus developing novel therapeutics that successfully target therapeutically refractory subpopulations is urgently needed to improve the outcome of GBM.
GBM contains self-renewing, multipotent subsets of tumor cells termed GBM-initiating or stem-like cells (GSC). 8 Accumulating evidence indicates that GSC play a central role in evading conventional treatments and causing tumor relapse, and thus represent an important therapeutic target. 9 In addition, GSC are able to recapitulate the genetic diversity seen in patients or the heterogeneity of tumor cells, and provide excellent preclinical GBM models, as opposed to traditional cell line based models that do not mirror clinical GBM. 10, 11 We have established a large panel of GBM "neurosphere" cell (GSC) lines that we isolated from patients, both from newly diagnosed as well as post-TMZ recurrent tumors. [12] [13] [14] [15] These lines grown as neurospheres are enriched for GSC, and retain patient-specific oncogenic molecular alterations such as EGFR amplification and the phenotypic hallmarks of GBM such as extensive invasiveness and angiogenesis. [12] [13] [14] [15] These patientderived newly diagnosed and recurrent GSC represent a unique resource that allows us to investigate the biology of therapeutic resistance and develop novel therapies to target GSC and overcome the challenge of tumor recurrence.
Oncolytic virus is genetically modified or naturally occurring virus that selectively replicates in and kills neoplastic cells while sparing normal cells. Genetically modified oncolytic herpes simplex virus (oHSV) is one of the most extensively investigated oncolytic viruses and the safety of administering oHSV in the human brain has been shown in clinical studies (reviewed in Ref. 16 ). Distinct mode of action renders oHSV a promising anti-cancer agent to overcome TMZ resistance; however, GBM cells differentially respond to oHSV-mediated oncolysis. 17 To target GBM cells that are not permissive to oHSV killing, we created a recombinant variant of oHSV, oHSV-TRAIL. 17 oHSV-TRAIL was engineered to express an anti-cancer protein, TNF-related apoptosis-inducing ligand (TRAIL). Providing multiple mechanisms of action, e.g., direct oncolysis and TRAIL-mediated apoptosis, oHSV-TRAIL showed potent anti-tumor activity in a mouse model of GBM. 17, 18 However the role of oHSV-TRAIL in the context of TMZ resistance has not been tested previously.
In this study we first screened a cohort of primary and recurrent patient-derived GSC lines for their sensitivity to TMZ. We next determined the molecular mechanisms that underlie oHSV-TRAIL mediated killing of chemoresistant GSC, and characterized the efficacy of oHSV-TRAIL in mouse GBM models derived from chemoresistant primary and recurrent GSC.
Material and Methods

Parental and engineered cell lines
Primary glioma neurosphere cell (GSC) lines (GSC4, GSC6,  GSC8, GSC18, GSC23, GSC29, GSC32, GSC34 and GSC64) ) and GSC23-Fluc-mCherry (GSC23-FmC) and GSC31-Fluc-mCherry (GSC31-FmC) lines were obtained after puromycin (1 lg mL
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) selection in culture.
Recombinant oHSVs and viral growth assay
G47D-empty (referred to oHSV in this study), G47D-mCherry (oHSV-mCherry), and G47D-TRAIL (oHSV-TRAIL) are BAC-based recombinant oHSV vectors with the genomic backbone of G47D (g34.5-, ICP6-, ICP47-). 17, [20] [21] [22] All of these oHSVs express E. coli lacZ driven by endogenous ICP6 promoter. oHSV bears no additional transgene sequences, while oHSV-mCherry and oHSV-TRAIL carry mCherry or soluble TRAIL (S-TRAIL) driven by the herpes simplex virus immediate early 4/5 promoter, respectively. S-TRAIL secretion from oHSV-TRAIL-infected Vero cells was confirmed by ELISA (26 
Immunocytochemistry
Differentiation of GSCs was induced by 7-day exposure to 5% fetal calf serum in DMEM. Staining for human nestin (Santa Cruz Biotechnology), GFAP (Sigma) and GalC (Chemicon) was performed as described previously.
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What's new? Genetically modified oncolytic herpes simplex virus is one of the most extensively investigated oncolytic viruses and safe to administer to the brain. Here the authors used a modified form that expresses the proapoptotic factor TRAIL to test its efficacy in preclinical glioblastoma models resistant to chemotherapy. They demonstrate robust and selective induction of apoptosismediated death in tumor cells and a 40% cure rate in mice carrying chemotherapy-resistant intracerebral glioblastoma pointing to potential clinical applications in the future.
In vitro cell viability assay
To determine the effects of TMZ, oHSV and oHSV-TRAIL on cell viability, GBM cells or NHA were seeded on 96-well plates (0.5 3 10 4 /well) and treated with different doses TMZ (0-1000 lM) or different MOIs of oHSV or oHSV-TRAIL 24 hr after plating. Cell viability was measured at indicated time points by determining the cell metabolic activity using an ATP-dependent luminescent reagent (CellTiter-Glo; Promega, Madison, WI) according to manufacturer's instructions. All experiments were performed in triplicates. reotactically implanted into the brains (right striatum, 2.5 mm lateral from bregma and 2.5 mm deep) of athymic mice (6 weeks of age). Tumor growth was monitored 1-2 times a week by Fluc bioluminescence (BLI) as described before. 23, 24 Tumor-bearing mice were intratumorally injected with 3 mL of 2.0 3 10 6 plaque-forming unit (pfu) of oHSV (n 5 5), oHSV-TRAIL (n 5 5), or PBS (n 5 4) to study tumor regression and brain pathology. For survival study, tumorbearing mice were intratumorally injected with 6 mL of 2.0 3 10 6 pfu of oHSV-TRAIL (n 5 6), or PBS (n 5 4) twice on days 14 and 26 after tumor cell implantation. Mice were imaged for Fluc BLI and followed for survival and sacrificed when neurological symptoms became apparent. Similarly, GSC31 (5 3 10 5 cells per mouse; n 5 10) were stereotactically implanted into the brains of athymic mice (6 weeks of age). Ten days post-implantation mice were injected intratumorally with 6 mL of 2.0 3 10 6 pfu of oHSV-TRAIL (n 5 5) or PBS (n 5 5). Mice were followed for survival and sacrificed when neurological symptoms became apparent. All in vivo procedures were approved by the institutional animal care and use committee (IACUC) at MGH.
Western blot analysis
Tissue processing and histopathological analysis
A set of mice with intracerebral GSC23-FmC and GSC31-FmC tumors were treated with intratumoral injections of PBS or oHSV-TRAIL on Day 39 (for GSC23-FmC) or on Day 59 (for GSC31-FmC) after tumor cell implantation (n 5 3-4 per group) as described above. About 48 hr after treatment mice were perfused with cold 4% paraformaldehyde via the heart and the brains were fixed in 4% paraformaldehyde. Frozen sections were obtained for hematoxylin and eosin staining and immunohistochemistry. The 5-bromo-4-choloro-3-indolyl-b-d-galactopyranoside (X-gal) staining was performed to identify lacZ-expressing infected cells followed by hematoxylin counterstaining. For cleaved caspase 3 and cleaved PARP staining, sections were incubated for 1 hr in a blocking solution (0.3% bovine serum albumin, 8% goat serum, and 0.3% Triton-X100) at room temperature, followed by incubation at 48C overnight with anti-cleaved caspase 3 (Cell Signaling) diluted in blocking solution. Sections were incubated in Alexa Fluor 488 goat anti-rabbit secondary antibody (Invitrogen), and visualized using a confocal microscope (LSM Pascal; Zeiss, Oberkochen, Germany). DAPI (Vectashield) was used to stain nuclei. The percentage of cleaved caspase 3 positive cells was calculated by counting positive cells in three randomly chosen miscroscopic fields.
Immunohistochemistry was used to stain human GBM cells and mouse neurons with anti-human specific nestin (Santa Cruz Biotechnology) and NeuN (Millipore) antibodies, respectively. Paraformaldehyde-fixed frozen sections were treated with acetone for 3 min followed by washes with PBS. After blocking with 2.5% horse serum (Vector Laboratories), sections were incubated with diluted primary antibodies at 48C overnight. After PBS washes, sections were incubated with ImmPRESS HRP anti-mouse IgG polymer (Vector Laboratories) for 1 hr at room temperature, followed by PBS washes and color development with DAB (Dako). Nuclei were counterstained with hematoxylin.
Statistical analysis
Data were analyzed by Student's t test when comparing two groups. Data were expressed as mean 6 SD and differences were considered significant at p < 0.05. Kaplan-Meier analysis was used for mouse survival studies, and the groups were compared using the log-rank test.
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Results
Screening of primary and recurrent patient-derived GSC lines identifies differential resistance to TMZ treatment
We first screened a panel of patient-derived GSC for their sensitivity to TMZ using in vitro cell viability assay. This panel of GSC includes 9 GSC lines that were established from primary (e.g., newly diagnosed) GBM (GSC4, 6, 8, 18, 23, 29, 32, 34 and 64), and 2 recurrent lines (GSC24R and 31) isolated from tumors that relapsed and progressed after the standard management regimens including TMZ chemotherapy. The ability of GSC to undergo multi-lineage differentiation was shown by immunofluorescence for GFAP (astrocyte marker) and GalC (oligodendrocyte marker) (Supporting Information Fig. S1 ). These GSC demonstrated variable sensitivities to TMZ, with 7 GSC lines (GSC18, 23, 24 R, 29, 31, 32 and 64) being resistant with their IC 50 values >300 lM, 1 line (GSC34) being semi-resistant, and 3 lines (GSC4, 6 and 8) being sensitive (IC 50 values <10 lM) (Fig. 1a) . As expected, both of the recurrent GSC tested (GSC24R, GSC31) were TMZ resistant. Expression of the TMZ-antagonizing enzyme MGMT was confirmed in TMZresistant GSC23 and GSC31. In conjunction with our prior report, MGMT expression was not detected in TMZ-sensitive GSC4, GSC6, GSC8 and GSC34 as well as TMZ-resistant GSC18 and GSC29 (Fig. 1b) .
14 These data show that primary GSC lines have varying sensitivities to TMZ, and recurrent GSC that underwent standard-of-care (radiation and TMZ) in the patients are resistant to TMZ.
oHSV-TRAIL is more potent than oHSV against TMZresistant GSC lines
To assess the cytotoxic activity of a proapoptotic variant of oHSV (oHSV-TRAIL) against TMZ-resistant primary and recurrent tumors, we tested 6 primary (GSC6, 18, 23, 29, 34 and 64) and 2 recurrent (GSC24R and 31) GSC lines. Although dose (multiplicity of infection, MOI)-dependent cytotoxicity was typically seen, efficiency in oHSV killing of GSC lines was variable and 5 of 8 GSC lines tested showed IC50 < MOI 1.0 (Fig. 2a) . oHSV-TRAIL was more efficacious than oHSV in 7 out of the 8 lines tested including the recurrent GSC, 24 R and 31 (Fig. 2a) . Treatment of TMZresistant GSC with an imaging variant of oHSV (oHSVmCherry (mCh)) showed an MOI-dependent increase in infectability (Supporting Information Fig. S2a) , and oHSVmCh spread over time within and between GSC spheres at low MOI 5 0.1 (Fig. 2bc) . oHSV-mCh spread poorly in Information Fig. S2b) , and oHSV and oHSV-TRAIL killing was modest in this line. GSC64 was the only line that did not respond to both oHSV and oHSV-TRAIL, and was found very poorly infectable (Supporting Information Fig. S2c ). oHSV and oHSV-TRAIL replicated similarly in GSCs, indicating that the expression of TRAIL does not compromise the replicative capability of oHSV (Fig.  2bc) . Replication of oHSV and oHSV-TRAIL was poor in normal human astrocytes (NHA) (Supporting Information  Fig. S3a) , and NHA were resistant to both viruses (Supporting Information Fig. S3b ). These data demonstrate the potent cytotoxic activity of oHSV-TRAIL in vitro against TMZresistant GSC derived from primary as well as recurrent GBM. On the basis of these studies, we selected two TMZresistant GSC lines, one primary and invasive (GSC23 14 ) and one recurrent (GSC31), for further studies.
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GSC29 (Supporting
oHSV-TRAIL targets cell proliferation, death and check point kinase signaling pathways in TMZ-resistant GSC Next, to assess whether oHSV-TRAIL induces perturbation of cell proliferation pathways in TMZ-resistant GSC, GSC23 and GSC31 were treated with oHSV or oHSV-TRAIL and analyzed. Western blot analysis revealed that oHSV and oHSV-TRAIL potently induced phosphorylation of JNK and p38 while the impacts of TMZ or TRAIL on these MAPK pathways were minimal (Fig. 3a) . oHSV and oHSV-TRAIL suppressed ERK1/2 phosphorylation in both GSC23 and GSC31, while TRAIL or TMZ did not (Fig. 3a) .
Because oHSV can provoke DNA damage response (DDR), 25 we assessed the activation of checkpoint kinase-1 (Chk1), a key effector in the cell cycle checkpoint pathway, in GSC. Strikingly, oHSV and oHSV-TRAIL treatment markedly decreased the levels of the Chk1 protein compared to TMZ- (Fig. 3b) . Importantly, greater induction of caspase 3 and PARP cleavage was seen in oHSV-TRAIL-treated GSC than in oHSV-treated GSC (Fig. 3c) . These results indicate that both oHSV and oHSV-TRAIL target cell proliferation pathway in a similar manner, but oHSV-TRAIL, not oHSV, induces caspase-3 cascade which results in efficient killing of both primary and recurrent patient-derived GSCs.
Determining critical pathways for oHSV-TRAIL killing effects through pharmacological small molecule inhibitors
We next sought to determine key signaling pathways or crosstalk that oHSV-TRAIL modifies to promote killing of GSC. We investigated whether targeted inhibition of MEK/ERK and/or Chk1 with highly selective inhibitor in conjunction with exogenous recombinant soluble TRAIL (S-TRAIL) could mimic the oHSV-TRAIL-mediated killing of GSC. Cell viability analysis using small molecule targeted agents against MEK/ERK and Chk1 individually, or in combination with S-TRAIL showed that triple combined treatment with MEK/ERK and Chk1 inhibitors and s-TRAIL effectively decreased cell viability in TMZresistant GSC23 and GSC31 compared with single treatment or the combination of any two (Fig. 3d) . These results reveal that oHSV-TRAIL-mediated inhibition of the ERK-MAPK and Chk1 signaling may contribute to oHSV-TRAIL-induced apoptotic cell death in chemo-resistant GBM cells. Thus oHSV-TRAIL as a single agent acts on and alters multiple pathways: (i) ERK1/2 inhibition (inhibition of proliferation), (ii) p38/JNK MAPK stimulation (stimulation of cell death/differentiation) and (iii) degradation of Chk1 preventing cell-cycle arrest and DNA damage repair pathways, and (iv) caspase-mediated apoptosis. Our results suggest that this simultaneous multi-pathway inhibition underlies the oHSV-TRAIL-mediated killing of TMZresistant GSC (Fig. 3e) .
oHSV-TRAIL inhibits GBM growth in vivo and prolongs survival of mice bearing primary invasive GBM derived from chemoresistant GSC To noninvasively monitor tumor progression and therapeutic effects in vivo, TMZ-resistant primary GSC23 was lentivirally engineered to express firefly luciferase (F) and mCherry (mCh). This genetic manipulation retained the ability of GSC to form neurospheres (Supporting Information Fig. S4a) , and did not alter sensitivity to TMZ (Supporting Information Fig.  S4b ) or oHSV-TRAIL-mediated killing efficiency in vitro (Supporting Information Fig. S4c ). In vivo, using an orthotopic tumor model in mice generated with GSC23-FmC, we first examined the anti-GBM activity of oHSV and oHSV-TRAIL. Bioluminescence imaging revealed that single intratumoral injections of oHSV and oHSV-TRAIL both mediated rapid regression of tumors, but with oHSV-TRAIL producing more robust effects (p < 0.05, Fig. 4a, Supporting Information  Fig. S5a) . This difference of anti-GBM activity between oHSV and oHSV-TRAL was associated with increased induction of cleaved caspase 3 by oHSV-TRAIL (Fig. 4b) . In oHSV-TRAIL-treated tumors, we observed areas of densely populated cleaved caspase 3 positive cells without mCherry expression, and confirmed that these were apoptotic and dying GBM cells by showing the immunopositivity of human nestin (Supporting Information Fig. S5b ). Cleaved PARP, downstream of the caspase-mediated apoptosis pathway, was detected in oHSV-TRAIL treated tumors, but not in PBS and oHSV treated tumors (Supporting Information Fig. S5c) . Importantly, we did not find neurotoxicity caused by injections of these viruses as there was neither noticeable change in the neuronal structure nor loss of neurons in the cerebral cortex of treated mice (Fig. 4c) . These observations provide a rationale to further investigate the molecular mechanisms and survival effects of oHSV-TRAIL therapy in vivo.
We next determined the therapeutic efficacy and underlying molecular mechanisms of oHSV-TRAIL. Mice bearing GSC23-FmC intracerebral tumors were treated with intratumoral injections of PBS or oHSV-TRAIL on days 14 and 26 after implantation (Fig. 4d) . BLI-assisted noninvasive tumor volume monitoring demonstrated that oHSV-TRAIL injections resulted in a significant decrease in tumor volumes compared to control (PBS) injections (Supporting Information Fig. S6a , p 5 0.01). Accordingly, oHSV-TRAIL treatment significantly prolonged the survival of animals; after treatment initiation, the median survival of oHSV-TRAIL-treated mice was 55 days, compared to 44 days with PBS-treated mice ( Fig. 4e ; p 5 0.015, log-rank test). Histopathological evaluation on brain sections collected 48-hr post PBS or oHSV-TRAIL injection showed massive cell death within the tumors treated with oHSV-TRAIL injections (Fig. 2f) . X-gal staining on adjacent sections showed a distribution of reporter b-galactosidase positivity, which overlapped with the tumor area, indicating the spread of oHSV-TRAIL (Fig. 2f) . Immunofluorescence analysis showed a striking increase in cleaved caspase 3 positivity in the sections prepared from oHSV-TRAIL-treated tumors as compared to PBS-treated tumors (Fig.  4gh , p 5 0.007). Cleaved caspase 3 staining was confined to tumor areas and not seen in host mouse cells, revealing tumor specificity of oHSV-TRAIL treatment (Fig. 4g) . Thus direct injections of oHSV-TRAIL mediated apoptotic cell death in chemoresistant GSC-derived invasive GBM in vivo, and provided substantive therapeutic benefits.
oHSV-TRAIL mediates robust tumor apoptosis and markedly prolongs survival of mice bearing orthotopic tumors generated with recurrent GSC Nearly 100% of GBM relapse after the current standard of care, and no effective therapy exists for recurrent GBM, which is typically associated with acquired resistance. Preclinical development of novel strategies for recurrent GBM is a challenge, and we took advantage of our unique GSC model isolated from recurrent GBM. Intracerebral tumors were generated with the recurrent GSC31 in athymic mice and were treated with intratumoral injections of PBS or oHSV-TRAIL on Day 10 (n 5 5 per group) (Fig. 5a ). Subsequent follow-up and survival analysis showed that all mice in the PBS group succumbed to tumor growth within 32 days with median survival of 26 days, revealing the malignant nature of the model (Fig. 5a) . In stark contrast, oHSV-TRAIL treatment resulted in much prolonged survival of GBM-bearing mice with the median survival of 81 days (p 5 0.0018, log-rank test) (Fig. 5a ). On Day 125 post implantation, 2 long-term surviving mice (40%) with oHSV-TRAIL treatment were euthanized and tumor cures were histologically confirmed.
We next generated intracerebral GSC31FmC xenografts, lentivirally expressing firefly luciferase (F) and mCherry (mC), in athymic mice, and serially monitored tumor growth with BLI. Mice were then randomized and treated with intratumoral injections of PBS (n 5 3) or oHSV-TRAIL (n 5 4) and 48 hr later the brains were harvested. In some of the mice subjected to BLI, we observed a drastic and rapid reduction of tumor signals following oHSV-TRAIL treatment (Supporting Information Fig. S6b ). X-gal staining of the brain sections showed an extensive distribution of reporter b-galactosidase positivity within tumor areas, revealing tumor-specific spread of oHSV-TRAIL (Fig. 5bc) . Immunofluorescence and confocal microscopy analysis demonstrated wide-spread positivity of cleaved caspase 3 staining on sections from oHSV-TRAIL-treated tumors as opposed to nearly no staining in PBS-treated tumors (p 5 0.0015), highlighting the highly efficient tumor apoptosis induction by oHSV-TRAIL (Fig. 5d-f) . Furthermore, no cleaved caspase 3 staining was seen in mCherry-negative normal brain cells confirming tumor-specific effect (Fig. 5de) . The extensive, tumor selective apoptosis induction and robust therapeutic activity observed in the aggressive recurrent GSC31 model suggest apoptosis induction as key to the efficacy of oHSV-TRAIL therapy. Our results thus demonstrate potent therapeutic activity of oHSV-TRAIL in vivo in a highly invasive primary GBM as well as an aggressive recurrent GBM model that represent chemoresistant tumors. 
Discussion
In this study, we identified patient-derived primary and recurrent GSC lines that are resistant to TMZ, and showed a potent therapeutic activity of oHSV-TRAIL against these refractory subsets of GBM cells. oHSV-TRAIL simultaneously alters cell proliferation, death and DDR pathways. In vivo, direct injections of oHSV-TRAIL prolong survival of mice bearing intracranial tumors derived from TMZ-resistant primary and recurrent GSC through robust induction of apoptotic cell death.
A body of evidence suggests that GSC contribute to therapeutic resistance and recurrence of GBM, and initial studies showed GSC are more resistant to TMZ than the bulk of tumor cells. 26 However, heterogenous responses of GSC to TMZ have been reported, and whether GSC generally resists chemotherapeutics remains controversial. 25, [27] [28] [29] Our screening of 11 patient-derived GSC lines revealed 7 as TMZ resistant. The recurrent GSC, 24 R and 31, were TMZ resistant, consistent with the fact that these were established from tumors that failed TMZ treatment in the patients. Six of the 7 TMZ-resistant GSC lines responded to oHSV in vitro, indicating that TMZ-resistance does not render GSC resistant to oHSV. Of note, oHSV-TRAIL exerted superior cytotoxic effects against these GSC lines including recurrent GSC. However, 1 GSC (GSC64) was resistant and another GSC (GSC29) was only marginally susceptible to oHSV-TRAIL, most likely due to poor viral infectivity and/or replication as shown in Supporting Information Figure S2 . Targeting these GSC with oHSV-TRAIL might require combinatorial approaches with agents such as chemotherapeutics or epigenetic modifiers (e.g., histone deacetylase inhibitors). 16, 30 In our earlier study we showed that oHSV-TRAIL targets MAPK signaling pathways in established GBM lines resistant to oHSV and TRAIL. 17 Here we confirmed oHSV and oHSV-TRAIL targeting of MAPK signaling pathways in TMZ-resistant primary and recurrent GSC. Interestingly, oHSV and oHSV-TRAIL infection markedly downregulates Chk1, a critical cell cycle checkpoint kinase that gets activated in response to DNA damage, in GSC. Previous studies have shown that HSV-1 phosphorylates and activates check kinase 2 (Chk2) and blocks the cell cycle in the G2/M phase to enhance viral replication. 31, 32 HSV-1 replication proteins disable ATR, inhibiting its phosphorylation of Replication protein A (RPA) and Chk1. 33, 34 On the other hand, HSV-1 activates the ATM signaling pathway, and the activated ATM-MRN complex colocalizes with HSV replication compartments. 25, 31, 35 HSVinduced depletion of the Chk1 protein could be due to degradation activity of HSV-encoded proteins. Indeed, the ubiquitin ligase activity of HSV proteins degrades the catalytic subunit of ATM through proteasome-dependent mechanisms. 36, 37 Our studies revealed an ability of oHSV-TRAIL to simultaneously inactivate MEK/ERK and Chk1 signaling pathways. Using highly selective inhibitors for MEK and Chk1, our studies support that the blockade of these pathways underlies the anti-GSC activity of oHSV-TRAIL. Active MEK/ERK signaling has been shown to interrupt Chk1 inhibitor activity against different tumors, and combination of MEK/ERK and Chk1 inhibitors was more effective than single inhibitors in treating multiple myeloma and GBM. 38, 39 Interestingly, adding S-TRAIL to this combination was co-operative in killing human leukemia cells as co-administration of TRAIL promoted mitochondrial dysfunction and apoptosis induced by Chk1 and MEK inhibitors. 40 This is in line with our data showing the triple combination of MEK/ERK inhibitor, Chk1 inhibitor, and S-TRAIL was more cytotoxic to GSC than any other combinations or monotherapies. These observations support that the multi-mechanistic action of oHSV-TRAIL underlies its apoptosis induction and efficient therapeutic targeting of refractory GBM cells. The oHSV-TRAIL disruption of multiple signaling pathways has promise in the treatment of GBM given GBM cells and GSC display sustained activation of multiple non-overlapping signaling pathways [41] [42] [43] [44] which might reflect disappointing results of many clinical trials testing specific targeted agents as monotherapy. 45 The detailed molecular mechanisms of oHSV-TRAIL will need to be validated by studies involving genetic silencing of Chk1 or ERK1/2 or overexpression of p38/JNK.
To assess the therapeutic efficacy of oHSV-TRAIL in orthotopic xenografts of chemoresistant GBM, we employed two models that each represents one of the two major challenges in clinical management of GBM, invasiveness and recurrence. Using a highly invasive model of GSC23 we showed that the treatment with oHSV-TRAIL significantly increased survival of tumor-bearing mice, which was consistent with our previous work that used the similarly invasive but TMZ-sensitive GSC8 model. 13 However, the therapeutic benefit was not robust and cures were not achieved. Insufficient oHSV delivery and spread to widely dispersed tumor cells represents a problem that could limit oHSV efficacy in highly invasive GBM. Repeated injections or convectionenhanced delivery of the virus might enhance the infection of tumor cells exhibiting extensive infiltration. 46 Extracellular matrix (ECM) within GBM can hamper intratumoral spread of oncolytic viruses by presenting physical barriers. 47 We recently demonstrated that an important component of ECM, hyaluronan, is abundant in GBM and an oncolytic virus expressing hyaluronidase mediates increased intratumoral spread and anti-GBM potency. 48 Simultaneous expression of TRAIL and hyaluronidase in the context of oHSV might overcome both resistance and delivery problems associated with oHSV therapy of highly invasive GBM. The second model we used to evaluate oHSV-TRAIL efficacy was derived from the recurrent GSC31. GSC31 is very resistant to TMZ (Fig. 1) and generates aggressive orthotopic tumors in mice that are noninvasive. Direct injection of oHSV-TRAIL had remarkable effects in the GSC31 model with a 40% cure rate, which was associated with extensive but tumor-specific induction of apoptosis as illustrated by cleaved caspase 3 staining (Fig. 5) . The particularly prominent therapeutic benefits of oHSV-TRAL seen in the recurrent GSC31 model may be associated with its non-invasive phenotype. Meisen et al. reported that oHSV therapy of GBM elicited TNF secretion by macrophages and microglia, which led to GBM apoptosis, suppressed oHSV replication and reduced efficacy. 49 However, we did not observe differences in the ability of oHSV and oHSV-TRAIL to replicate in GSC in vitro despite oHSV-TRAIL induction of apoptosis, which may reflect the in vivo efficacy of oHSV-TRAIL. Recurrent GBM that progressed after radiation and TMZ chemotherapy has been shown to have distinct molecular characteristics that include increased expression of stemness or mesenchymal markers, 50, 51 and a hypermutator phenotype caused primarily by TMZ. 52 Therefore, newly diagnosed and recurrent GBM can exhibit differential response to treatment. Because most clinical trials testing investigational agents including oncolytic virus are initially designed for recurrent disease, use of recurrent GBM model for preclinical assessment is relevant and can be of predictive value. Thus, demonstration of strong efficacy of oHSV-TRAIL in a patient-derived recurrent GSC-based intracerebral model provides immediate translational implications. We have established a cohort of patientderived recurrent GSC lines that display diverse biological phenotypes (e.g., invasive and nodular) and genotypes, 12, 15 (unpublished work), offering a useful platform to test experimental therapeutics. Studying oHSV-TRAIL in these models will allow us to better understand its mechanisms, efficacy and limitations in clinically representative settings. These efforts could lead us to a clinical trial testing oHSV-TRAIL for GBM patients, which ultimately may change the therapeutic paradigm for this devastating malignancy.
